Population pharmacokinetics and exposure-response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer

• Main Authors: Yinhui Liu (Author), Yan Tan (Author), Lin Hu (Author), Jinlong Li (Author), Jiansong Yang (Author), Lei Diao (Author), Jin Yang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ObjectiveSAF-189s is a potent ALK/ROS1 inhibitor that is currently in clinical development for treating advanced ALK+/ROS1+ non-small cell lung cancer (NSCLC). Comprehensive population pharmacokinetics (PopPK) and exposure-response models were developed to evaluate the efficacy and safety of SAF-189...